Cost-effectiveness of adalimumab (Humira™) in the treatment of US patients with rheumatoid arthritis (RA)

被引：1
|
作者：
Bansback, N
Brennan, A
Sengupta, N
机构：
[1] Univ Sheffield, Sheffield S10 2TN, S Yorkshire, England
[2] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
VALUE IN HEALTH | 2004年 / 7卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)62129-8
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：241 / 241
页数：1
相关论文
共 50 条
  • [11] COST-EFFECTIVENESS OF ADALIMUMAB FOR RHEUMATOID ARTHRITIS IN GERMANY
    Gissel, C.
    VALUE IN HEALTH, 2014, 17 (03) : A48 - A48
  • [12] The cost effectiveness of adalimumab (HUMIRA®) in UK patients with moderate to severe RA
    Bansback, NJ
    Brennan, A
    Sengupta, N
    Pang, F
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 512 - 513
  • [13] Cost-Effectiveness of Adalimumab for Rheumatoid Arthritis in Germany.
    Gissel, Christian
    Goetz, Georg
    Repp, Holger
    Lange, Uwe
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S503 - S503
  • [14] Remission and major clinical response in active rheumatoid arthritis (RA) patients after adalimumab (Humira®) treatment
    Burmester, G. M.
    Wordsworth, P.
    McKenna, F.
    Farraccioli, G. F.
    Flipo, R. -M.
    Kary, S.
    Kupper, H.
    RHEUMATOLOGY, 2007, 46 : I28 - I29
  • [15] The cost effectiveness of adalimumab (HUMIRA®) vs. infliximab (REMICADE) in achieving clinical response at 1 and 3 years in patients with early rheumatoid arthritis (RA):: US analysis
    Davies, AS
    Hutton, J
    Cifaldi, MA
    Pang, F
    Spencer-Green, G
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 393 - +
  • [16] Adalimumab (Humira) for rheumatoid arthritis
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2003, 45 (1153): : 25 - 27
  • [17] Remission and major clinical response in patients with active rheumatoid arthritis (RA) after treatment with adalimumab (Humira®).
    Burmester, G. M.
    Ferraccioli, G. F.
    Flipo, R-M
    Kary, S.
    Kupper, H.
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S377 - S377
  • [18] COST-EFFECTIVENESS OF RITUXIMAB VS ADALIMUMAB IN THE TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS
    Bynum, L. A.
    Joshi, N.
    VALUE IN HEALTH, 2010, 13 (03) : A126 - A126
  • [19] Sustained efficacy of adalimumab (HUMIRA™) plus methotrexate in rheumatoid arthritis (RA) patients.
    Schiff, MH
    Weisman, MH
    Furst, DE
    Kavanaugh, A
    Fischkoff, SA
    Spencer-Green, GT
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S314 - S315
  • [20] Adalimumab (HUMIRA®) monotherapy significantly improves fatigue in patients with severe rheumatoid arthritis (RA)
    Dietz, BM
    Sterz, R
    Holtbrügge, W
    Kupper, H
    Van de Putte, LBA
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 392 - +
12345